Stocks and Investing Stocks and Investing
Mon, July 24, 2023
Sun, July 23, 2023
Fri, July 21, 2023

Brendan Smith Initiated (ARWR) at Buy on, Jul 21st, 2023


Published on 2024-10-28 05:02:18 - WOPRAI, Brendan Smith
  Print publication without navigation


Brendan Smith of TD Cowen, Initiated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Buy on, Jul 21st, 2023.

Brendan has made no other calls on ARWR in the last 4 months.



There are 10 other peers that have a rating on ARWR. Out of the 10 peers that are also analyzing ARWR, 3 agree with Brendan's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Downgraded from Buy to Hold and Held Target at $40 on, Friday, May 12th, 2023
  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $40 on, Wednesday, May 3rd, 2023
  • William Pickering of "Bernstein" Initiated at Hold and Held Target at $27 on, Tuesday, March 21st, 2023


These are the ratings of the 7 analyists that currently disagree with Brendan


  • Mayank Mamtani of "B. Riley Securities" Reiterated at Strong Buy and Held Target at $55 on, Thursday, July 20th, 2023
  • Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $90 on, Friday, June 30th, 2023
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $59 on, Friday, June 2nd, 2023
  • Keay Nakae of "Chardan Capital" Reiterated at Strong Buy and Held Target at $60 on, Friday, June 2nd, 2023
  • Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $60 on, Wednesday, May 3rd, 2023
  • Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $73 on, Wednesday, May 3rd, 2023
  • David Hoang of "SMBC Nikko" Initiated at Buy and Held Target at $80 on, Wednesday, April 26th, 2023
Contributing Sources